December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,437.29 +5.00 (+0.35%)
Official Closing Price Updated: 7:00 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly (LLY) Q3 2026 Earnings Call Transcript ↗
Revenue surged 39% on blockbuster obesity drug demand and strong international growth. 
Via The Motley Fool
Topics Earnings
S&P 500 Top Movers: Oct. 29, 2026 Gainers and Losers ↗
Via Chartmill
Topics Stocks
News headline image
Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reaction ↗
Eli Lilly’s realized prices fell 15%, but a 53% jump in volume pushed revenue up 39% and lifted full-year guidance by $5.5 billion. Here’s why the math works, and what could break it. 
Via The Motley Fool
Eli Lilly (NYSE:LLY) Beats Q3 Estimates, Raises Guidance as Shares Jump ↗
Via Chartmill
S&P 500 Top Movers: Today's US Session Gainers and Losers ↗
Via Chartmill
Topics Stocks
S&P 500 Gap Movers: October 29, 2026 Session ↗
Via Chartmill
Topics Stocks
News headline image
Eli Lilly (LLY) shares skyrocket, what you need to know
What happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 8.1% in the morning session after the company reported third-quarter 2026 ... 
Via StockStory
News headline image
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments. 
From FN Media
Via GlobeNewswire
News headline image
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance ↗
Eli Lilly stock jumped early Thursday on a solid third-quarter report on the back of Mounjaro and Zepbound. 
Via Investor's Business Daily
News headline image
Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 38.6% year on year to... 
Via StockStory
News headline image
Could Revolution Medicines Be a Millionaire-Maker Stock? ↗
The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one. 
Via The Motley Fool
News headline image
Eli Lilly's Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test ↗
Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study. 
Via Investor's Business Daily
News headline image
Eli Lilly (LLY) reports earnings tomorrow: what to expect
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before market hours. Here’s what you need to know. Eli Lilly beat... 
Via StockStory
Topics Artificial Intelligence
News headline image
$10,000 Invested in Eli Lilly 5 Years Ago Would Be Worth This Much Today ↗
The company has made longtime shareholders much richer. 
Via The Motley Fool
Topics ETFs
News headline image
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? ↗
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity’s FHLC or State Street’s XLV? ↗
XLV concentrates on 61 large-cap S&P 500 names, while FHLC casts a wider net with 365 holdings across mid and small caps. Both charge 0.08% annually. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? ↗
Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It. ↗
Tech stocks are selling off as investors question the payoff of artificial intelligence (AI) infrastructure spending. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
News headline image
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks) ↗
These drugmakers are capitalizing on their pipeline successes. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly's Fast Growth Hasn't Slowed Its Progress As Sustainability Leader ↗
Eli Lilly's commitment to philanthropy, coupled with a dedication to environmental progress, make it a sustainability leader. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk. 
Via MarketBeat
News headline image
The S&P 500 May Depend on the Fortunes of These 3 Companies Right Now. Here’s the Good News and the Bad News for Investors. ↗
These companies make up about 20% of the index. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? ↗
Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story. 
Via The Motley Fool
News headline image
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results? ↗
Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants. 
Via The Motley Fool
Topics Artificial Intelligence Lawsuit
News headline image
Vanguard Health Care ETF vs iShares U.S. Healthcare ETF ↗
VHT's 411 holdings and 0.09% expense ratio deliver identical 5-year returns to IYH's concentrated 100-stock portfolio, raising questions about whether lower costs justify broader diversification. 
Via The Motley Fool
Topics ETFs
News headline image
Where Will Novo Stock Be in 10 Years? ↗
The company may lean on its core therapeutic area to help it overcome recent headwinds. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs ↗
Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers. 
Via MarketBeat
Topics Artificial Intelligence ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.